A Phase I/II Trial of CLT-008 Myeloid Progenitor Cells in Patients Receiving Post-remission Therapy for High Risk Leukemia or Myelodysplasia
Phase of Trial: Phase I/II
Latest Information Update: 04 May 2015
Price : $35 *
At a glance
- Drugs Romyelocel-L (Primary) ; Filgrastim
- Indications Neutropenia
- Focus Adverse reactions
- Sponsors Cellerant Therapeutics
- 01 Sep 2014 Status changed from active, no longer recruiting to completed.
- 21 Aug 2014 Planned End Date changed to 1 Jan 2015 as reported by ClinicalTrials.gov.
- 21 Aug 2014 Planned primary completion date changed from 1 Mar 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.